Tempus AI Launches Digital Pathology Consortium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
Tempus AI's stock fell 8.27% as it crossed below the 5-day SMA amid a broader market decline, with the Nasdaq-100 down 2.66% and the S&P 500 down 1.39%.
The decline in Tempus AI's stock price comes despite the recent launch of the digital pathology IMS Open-Source Consortium, which aims to enhance clinical adoption of digital pathology solutions. This consortium, formed with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, is expected to drive innovation and collaboration in the field, potentially benefiting Tempus in the long run. However, the current market conditions have overshadowed this positive development, leading to a significant drop in the stock price.
The implications of this consortium could be substantial for Tempus AI, as it positions the company at the forefront of digital pathology advancements. However, the immediate market reaction reflects broader investor sentiment and concerns, which may require time to stabilize as the consortium's impact unfolds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 48.820
Low
76.00
Averages
84.38
High
105.00
Current: 48.820
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus AI Aims for Profitable Growth Potential Beyond Diagnostics
- Business Expansion Potential: Tempus AI is striving to build a healthcare data platform that goes beyond diagnostics, integrating AI tools and pharmaceutical partnerships, which could lead to significant profit growth if successfully scaled.
- FDA Progress Impact: The company's advancements with the FDA support market access for its products, and if successfully navigated, could enhance investor confidence and market competitiveness.
- High Expectations Reflection: Although market expectations for Tempus AI are already quite high, execution capability will be a key concern for investors, as success or failure will directly impact stock performance.
- Investor Recommendations: The analyst team has noted that Tempus AI was not included in the current list of top investment stocks, indicating a cautious market sentiment regarding its future performance, prompting investors to carefully assess its investment value.
See More
ExomeReveal RNA Analysis Enhances Genetic Diagnosis Clarity
- Significant Research Findings: Ambry Genetics' study demonstrates that RNA analysis through the ExomeReveal workflow can provide clearer diagnoses for nearly 2,000 genetic variants, particularly as about 10% of these variants were suspected to affect gene splicing, highlighting the necessity and efficacy of RNA testing.
- Resolving Uncertain Variants: Among patients participating in follow-up RNA testing, approximately 8% of variants qualified for further RNA analysis, with more than one-third originally classified as Variants of Uncertain Significance, indicating the critical role of RNA testing in clinical applications.
- Clinical Decision Support: The study emphasizes that combining RNA with exome sequencing offers visibility into molecular-level information, aiding physicians in making more precise clinical decisions, thus meeting the needs of patients and their families for clear answers and enhancing patient care quality.
- Future Application Prospects: The proposed criteria for RNA testing provide guidance for widespread adoption across clinical laboratories, indicating that integrating RNA testing into diagnostic pipelines is achievable and impactful, potentially transforming the diagnosis of genetic diseases.
See More
Tempus AI Expands Beyond Diagnostics with Healthcare Data Platform
- Business Expansion Strategy: Tempus AI is striving to move beyond traditional diagnostics by building a growing healthcare data platform integrated with AI tools, aiming for sustainable profit growth that enhances its market competitiveness.
- FDA Progress: The company's advancements with the FDA provide crucial support for market access of its products, and successful navigation of this process could significantly boost investor confidence and drive stock price appreciation.
- Pharma Partnerships: Tempus AI's deepening partnerships with pharmaceutical companies not only facilitate the application of its technologies but also have the potential to generate new revenue streams, further driving business diversification.
- Market Expectation Challenges: Despite the promising outlook, the current stock price reflects high market expectations, making execution capability a key focus for investors, which will ultimately determine future stock price movements.
See More
AstraZeneca CEO Discusses AI's Role in Drug Development
- AI Enhances R&D Efficiency: AstraZeneca CEO Pascal Soriot stated that artificial intelligence is accelerating the drug development process, enabling faster and smarter design of new medicines, thereby improving productivity to meet urgent market demands.
- Optimizing Drug Design: With AI technology, AstraZeneca can identify new targets and optimize molecular structures by removing potential side effects, which not only enhances drug safety but also increases the likelihood of successful development, holding significant competitive market implications.
- Data-Driven Decision Making: The partnership with Tempus AI allows AstraZeneca to leverage AI models to analyze clinical and laboratory data, thereby better predicting the success probability of Phase 3 trials, reducing development risks and enhancing investment returns.
- Significant Economic Benefits: Soriot highlighted that drug trials typically cost between $300 million and $500 million, and by increasing the probability of success, the application of AI will yield enormous productivity improvements, significantly enhancing the company's financial performance.
See More
Tempus AI Launches Digital Pathology Open-Source Consortium
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
See More
Tempus AI Launches Next-Generation Genetic Test for Oncology
- Clinical Availability Boost: Tempus AI announces the upcoming launch of the xH test, which utilizes whole-genome sequencing to detect actionable oncologic targets in blood and bone marrow samples, expected to significantly enhance diagnostic efficiency for patients with hematologic malignancies.
- Validation Study Results: In an analytical validation study involving 235 unique specimens, the xH test achieved a positive percent agreement of 97.29% for SNVs and Indels, demonstrating high accuracy across multiple variant classes and bolstering confidence in its clinical application.
- Sensitivity and Discovery Rate: In a blinded study of an MDS cohort, the xH test achieved over 99% sensitivity and uncovered more than 40% of clinically relevant genomic variations that were missed by traditional methods, highlighting its superiority in guiding clinical decisions.
- Strategic Goal Achievement: Tempus CEO Tom Schonherr stated that the launch of the xH test marks the realization of the company's vision in hematologic oncology, streamlining diagnostic processes to enable faster decision-making for clinicians while providing biopharma partners with a multiomic foundation to enhance clinical trial design and targeted therapy development.
See More
Tempus AI Aims for Profitable Growth Potential Beyond Diagnostics
- Business Expansion Potential: Tempus AI is striving to build a healthcare data platform that goes beyond diagnostics, integrating AI tools and pharmaceutical partnerships, which could lead to significant profit growth if successfully scaled.
- FDA Progress Impact: The company's advancements with the FDA support market access for its products, and if successfully navigated, could enhance investor confidence and market competitiveness.
- High Expectations Reflection: Although market expectations for Tempus AI are already quite high, execution capability will be a key concern for investors, as success or failure will directly impact stock performance.
- Investor Recommendations: The analyst team has noted that Tempus AI was not included in the current list of top investment stocks, indicating a cautious market sentiment regarding its future performance, prompting investors to carefully assess its investment value.
See More
ExomeReveal RNA Analysis Enhances Genetic Diagnosis Clarity
- Significant Research Findings: Ambry Genetics' study demonstrates that RNA analysis through the ExomeReveal workflow can provide clearer diagnoses for nearly 2,000 genetic variants, particularly as about 10% of these variants were suspected to affect gene splicing, highlighting the necessity and efficacy of RNA testing.
- Resolving Uncertain Variants: Among patients participating in follow-up RNA testing, approximately 8% of variants qualified for further RNA analysis, with more than one-third originally classified as Variants of Uncertain Significance, indicating the critical role of RNA testing in clinical applications.
- Clinical Decision Support: The study emphasizes that combining RNA with exome sequencing offers visibility into molecular-level information, aiding physicians in making more precise clinical decisions, thus meeting the needs of patients and their families for clear answers and enhancing patient care quality.
- Future Application Prospects: The proposed criteria for RNA testing provide guidance for widespread adoption across clinical laboratories, indicating that integrating RNA testing into diagnostic pipelines is achievable and impactful, potentially transforming the diagnosis of genetic diseases.
See More
Tempus AI Expands Beyond Diagnostics with Healthcare Data Platform
- Business Expansion Strategy: Tempus AI is striving to move beyond traditional diagnostics by building a growing healthcare data platform integrated with AI tools, aiming for sustainable profit growth that enhances its market competitiveness.
- FDA Progress: The company's advancements with the FDA provide crucial support for market access of its products, and successful navigation of this process could significantly boost investor confidence and drive stock price appreciation.
- Pharma Partnerships: Tempus AI's deepening partnerships with pharmaceutical companies not only facilitate the application of its technologies but also have the potential to generate new revenue streams, further driving business diversification.
- Market Expectation Challenges: Despite the promising outlook, the current stock price reflects high market expectations, making execution capability a key focus for investors, which will ultimately determine future stock price movements.
See More
AstraZeneca CEO Discusses AI's Role in Drug Development
- AI Enhances R&D Efficiency: AstraZeneca CEO Pascal Soriot stated that artificial intelligence is accelerating the drug development process, enabling faster and smarter design of new medicines, thereby improving productivity to meet urgent market demands.
- Optimizing Drug Design: With AI technology, AstraZeneca can identify new targets and optimize molecular structures by removing potential side effects, which not only enhances drug safety but also increases the likelihood of successful development, holding significant competitive market implications.
- Data-Driven Decision Making: The partnership with Tempus AI allows AstraZeneca to leverage AI models to analyze clinical and laboratory data, thereby better predicting the success probability of Phase 3 trials, reducing development risks and enhancing investment returns.
- Significant Economic Benefits: Soriot highlighted that drug trials typically cost between $300 million and $500 million, and by increasing the probability of success, the application of AI will yield enormous productivity improvements, significantly enhancing the company's financial performance.
See More
Tempus AI Launches Digital Pathology Open-Source Consortium
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
See More
Tempus AI Launches Next-Generation Genetic Test for Oncology
- Clinical Availability Boost: Tempus AI announces the upcoming launch of the xH test, which utilizes whole-genome sequencing to detect actionable oncologic targets in blood and bone marrow samples, expected to significantly enhance diagnostic efficiency for patients with hematologic malignancies.
- Validation Study Results: In an analytical validation study involving 235 unique specimens, the xH test achieved a positive percent agreement of 97.29% for SNVs and Indels, demonstrating high accuracy across multiple variant classes and bolstering confidence in its clinical application.
- Sensitivity and Discovery Rate: In a blinded study of an MDS cohort, the xH test achieved over 99% sensitivity and uncovered more than 40% of clinically relevant genomic variations that were missed by traditional methods, highlighting its superiority in guiding clinical decisions.
- Strategic Goal Achievement: Tempus CEO Tom Schonherr stated that the launch of the xH test marks the realization of the company's vision in hematologic oncology, streamlining diagnostic processes to enable faster decision-making for clinicians while providing biopharma partners with a multiomic foundation to enhance clinical trial design and targeted therapy development.
See More
